Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Stomach (gastric) cancer
Stage/Subtype:  stage IV gastric cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 47 for your search:
Start Over
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO27952, NCI-2013-00507, 2012-000660-22, NCT01641939
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00021, NCI-2015-00590, NCT02340975
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Afatinib Dimaleate and Trastuzumab in Treating Patients with Refractory Metastatic Esophagus or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
Biomarkers in Predicting Response to Docetaxel, Cisplatin, and Fluorouracil in Patients With Metastatic Esophagus, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: J1248/ NA_00073720, NCI-2013-00058, J1248, NCT01715233
Combination Chemotherapy in Treating Patients with Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201309035, NCI-2013-01783, NCT01928290
Dacomitinib in Treating Patients with Progressive Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCSD 130418, NCI-2014-00818, 130418, DP01-WS2043189, NCT02047747
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C26002, NCI-2014-01745, 2014-000804-88, REec-2014-1176, U1111-1155-9023, NCT02202759
Nintedanib in Treating Patients with Advanced Esophageal, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-094, NCI-2014-01964, NCT02234596
Afatinib and Paclitaxel in Treating Patients with HER2-Positive Recurrent Advanced Gastric, Gastroesophageal Junction, or Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAM5905, NCI-2015-00758, 1200.203, NCI-2014-02350, NCT02274012
Personalized Therapy Using Genetic Markers in Treating Patients with Esophagogastric Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412051, NCI-2014-02550, NCT02296671
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-059, NCI-2015-00402, 2014-003574-16, NCT02335411
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Start Over